P1202: INTENDED USE OF GLUCARPIDASE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND IMPAIRED RENAL FUNCTION – THE VALIDATE STUDY

• S. Liebig,
• S. Burock,
• I. Merz,
• F. Knörnschild,
• P. Kießling,
• K. Kappert,
• U. Keller,
• S. Schwartz

Affiliations

S. Liebig

1 Department of Hematology, Oncology and Tumorimmunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin

S. Burock

2 Charité Comprehensive Cancer Center, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin

I. Merz

1 Department of Hematology, Oncology and Tumorimmunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin

F. Knörnschild

1 Department of Hematology, Oncology and Tumorimmunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin

P. Kießling

3 Labor Berlin, Charité Vivantes GmbH

K. Kappert

3 Labor Berlin, Charité Vivantes GmbH

U. Keller

1 Department of Hematology, Oncology and Tumorimmunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin

S. Schwartz

1 Department of Hematology, Oncology and Tumorimmunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Benjamin Franklin